Biofrontera Inc.
$1.09
▲
6.41%
2026-04-21 05:38:00
www.biofrontera-us.com
NCM: BFRI
Explore Biofrontera Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.81 M
Current Price
$1.09
52W High / Low
$1.19 / $0.54
Stock P/E
—
Book Value
$0.9
Dividend Yield
—
ROCE
-68.08%
ROE
-1.41%
Face Value
—
EPS
$-1.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
84
Beta
0.64
Debt / Equity
58.79
Current Ratio
1.52
Quick Ratio
1.4
Forward P/E
-4.48
Price / Sales
0.29
Enterprise Value
$11.76 M
EV / EBITDA
-1.05
EV / Revenue
0.28
Rating
None
Target Price
$6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TherapeuticsMD, Inc. | $2.19 | 83.93 | $25.35 M | — | -12.82% | -2.41% | $2.95 / $0.95 | $2.32 |
| 2. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 3. | Prestige Consumer Healthcare Inc. | $58.68 | 14.89 | $2.78 B | — | 10.6% | 10.31% | $89.37 / $51.24 | $38.66 |
| 4. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
| 5. | Sunshine Biopharma, Inc. | $1.02 | — | $5.05 M | — | -23.97% | -25.68% | $2.43 / $0.95 | $5.31 |
| 6. | Zhengye Biotechnology Holding Limited | $0.95 | — | $47.54 M | 0.05% | 4.81% | -6.38% | $14.3 / $0.68 | $0.91 |
| 7. | ANI Pharmaceuticals, Inc. | $81.73 | 23.13 | $1.81 B | 0.06% | 6.99% | 16.16% | $99.5 / $56.71 | $25.8 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.1 M | 6.99 M | 9.03 M | 8.59 M | 12.56 M | — |
| Operating Profit | 4.56 M | -6.28 M | -5.08 M | -4.55 M | -1.71 M | — |
| Net Profit | 5.64 M | -6.65 M | -5.32 M | -4.2 M | -1.4 M | — |
| EPS in Rs | 0.48 | -0.57 | -0.46 | -0.36 | -0.12 | -0.98 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 41.7 M | 37.32 M | 34.07 M | 28.67 M |
| Operating Profit | -11.35 M | -17.21 M | -22.58 M | -22.38 M |
| Net Profit | -10.54 M | -17.76 M | -20.13 M | -0.64 M |
| EPS in Rs | -0.9 | -1.52 | -1.73 | -0.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 28.56 M | 22.1 M | 27.93 M | 50.88 M |
| Total Liabilities | 18.08 M | 17.67 M | 23.14 M | 27.01 M |
| Equity | 10.48 M | 4.43 M | 4.79 M | 23.88 M |
| Current Assets | 18.08 M | 20.7 M | 23.07 M | 43.14 M |
| Current Liabilities | 11.89 M | 12.02 M | 18.09 M | 20.89 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.36 M | -10.27 M | -24.89 M | -16.2 M |
| Investing CF | 3 M | -0 M | 0.62 M | -5.16 M |
| Financing CF | 10.85 M | 14.84 M | 8.41 M | 14.02 M |
| Free CF | -13.36 M | -10.33 M | -24.9 M | -16.24 M |
| Capex | -0 M | -0.06 M | -0.01 M | -0.04 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.54% | 18.82% | — | — |
| Earnings Growth % | 11.78% | -3045.47% | — | — |
| Profit Margin % | -47.58% | -59.09% | -2.23% | — |
| Operating Margin % | -46.11% | -66.26% | -78.05% | — |
| Gross Margin % | 50.14% | 48.8% | 47.04% | — |
| EBITDA Margin % | -38.99% | -54.16% | 3.26% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-07-05 | 1:0.05 |